Kezar Life Sciences Receives $23,000,000 Series A Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9a4cb7ad-e2c4-42fb-bbab-f6fdabc67cf7
Date
6/18/2015
Company Name
Kezar Life Sciences
Mailing Address
300 Utah Avenue South San Francisco, CA 94080 USA
Company Description
Kezar Life Sciences, a privately held company based in South San Francisco, was founded in 2015 to develop drugs to revolutionize the treatment of autoimmune disorders.
Website
http://www.kezarbio.com
Transaction Type
Venture Equity
Transaction Amount
$23,000,000
Transaction Round
Series A
Proceeds Purposes
The capital raised in the Series A will be used to advance Kezar’s lead immunoproteasome inhibitor candidate into Phase 1a and 1b clinical trials, with the goal of demonstrating safety and efficacy in patients with autoimmune disease.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor